Mariner
GLUE icon

Mariner’s Monte Rosa Therapeutics GLUE Stock Holding History

Mariner’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$282K Sell
17,117
-4,483
-21% -$85.7K ﹤0.01% 2929
2025
Q4 		$340K Buy
21,600
+7,837
+57% +$106K ﹤0.01% 2738
2025
Q3 		$102K Sell
13,763
-1,096
-7% -$5.8K ﹤0.01% 3352
2025
Q2 		$67K Buy
+14,859
New +$66.3K ﹤0.01% 3301

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Mariner's GLUE Position: Q1 2026 in Review

Mariner reduced its Monte Rosa Therapeutics (GLUE) stake by 21% in Q1 2026, selling an estimated $85.7K and leaving 17,117 shares worth $282K. The position accounts for ﹤0.01% of the portfolio, ranked #2929.

Mariner first reported a position in GLUE in Q2 2025 and has held it in 4 quarters since. The position peaked at $340K in Q4 2025. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Mariner held 17,117 shares of Monte Rosa Therapeutics worth $282K as of Q1 2026.
  • Mariner sold 4,483 Monte Rosa Therapeutics shares in Q1 2026, an estimated $85.7K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Mariner's portfolio in Q1 2026, its #2929 holding.
  • Mariner first reported a position in Monte Rosa Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Mariner's Monte Rosa Therapeutics position peaked at $340K in Q4 2025.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.